Lyophilized mRNA-LNP Stability via Ascorbic Acid and Temperature Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lipid nanoparticle delivery of encapsulated messenger RNA (mRNA) faces challenges due to mRNA's instability and sensitivity to temperature, requiring effective methods for maintaining mRNA integrity during storage.
Innovation Solution
The process involves adding ascorbic acid, pretreating the mRNA-LNP composition with a buffer to maintain pH, and increasing the temperature of the lyophilized composition during the secondary drying step to improve mRNA integrity, resulting in a stable lyophilized mRNA-LNP composition that withstands long-term storage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If mRNA is encapsulated in lipid nanoparticles for delivery, then therapeutic application is enabled, but mRNA integrity deteriorates due to instability and temperature sensitivity
Solution Approach 1:
The patent applies preliminary action by adding ascorbic acid to the mRNA-LNP formulation before lyophilization. This antioxidant is pre-introduced to protect mRNA from oxidative degradation during subsequent storage and processing, preventing damage before it occurs rather than responding to degradation after it happens.
Solution Approach 2:
The patent employs parameter changes by optimizing the lyophilization process parameters including temperature profiles (secondary drying at elevated temperatures), pH control through buffer pretreatment, and ascorbic acid concentration. These parameter optimizations maintain mRNA integrity while enabling stable lyophilized formulation.
2Duration of action of stationary object
If lyophilization is performed to improve storage stability, then long-term storage is enabled, but mRNA integrity may be lost during the drying process
Solution Approach 1:
The patent applies preliminary action by adding ascorbic acid to the mRNA-LNP formulation before lyophilization. This antioxidant is pre-introduced to protect mRNA from oxidative degradation during subsequent storage and processing, preventing damage before it occurs rather than responding to degradation after it happens.
Solution Approach 2:
The patent employs parameter changes by optimizing the lyophilization process parameters including temperature profiles (secondary drying at elevated temperatures), pH control through buffer pretreatment, and ascorbic acid concentration. These parameter optimizations maintain mRNA integrity while enabling stable lyophilized formulation.
3Reliability
If ascorbic acid is added to protect mRNA during lyophilization, then mRNA integrity is improved, but formulation complexity increases
Solution Approach 1:
The patent uses ascorbic acid as an intermediary substance that mediates between the mRNA and the harsh lyophilization conditions. The antioxidant acts as a protective intermediary that absorbs oxidative stress during drying, allowing the mRNA to withstand the process without direct damage.
Solution Approach 2:
The patent employs parameter changes by optimizing the lyophilization process parameters including temperature profiles (secondary drying at elevated temperatures), pH control through buffer pretreatment, and ascorbic acid concentration. These parameter optimizations maintain mRNA integrity while enabling stable lyophilized formulation.
4Productivity
If secondary drying is performed at high temperature to remove moisture, then lyophilization efficiency is improved, but mRNA degradation may occur
Solution Approach 1:
The patent applies preliminary action by adding ascorbic acid to the mRNA-LNP formulation before lyophilization. This antioxidant is pre-introduced to protect mRNA from oxidative degradation during subsequent storage and processing, preventing damage before it occurs rather than responding to degradation after it happens.
Solution Approach 2:
The patent employs parameter changes by optimizing the lyophilization process parameters including temperature profiles (secondary drying at elevated temperatures), pH control through buffer pretreatment, and ascorbic acid concentration. These parameter optimizations maintain mRNA integrity while enabling stable lyophilized formulation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly enhances mRNA integrity post-lyophilization, maintaining it at high levels even after reconstitution, ensuring effective short- and long-term storage with minimal degradation.
Implementation Method 1
adding ascorbic acid for lyophilization process
Implementation Method 2
freezing the aqueous solution to obtain a frozen solution
Implementation Method 3
lyophilization process
Implementation Method 4
increasing and holding the temperature of the lyophilized composition (e.g., during the secondary drying step) to a high temperature
Data Source
AI summary
The present invention provides an improved process for preparing a stable lyophilized composition comprising lipid nanoparticles encapsulating mRNA, which results in high mRNA integrity suitable for both short- and long-term storage for therapeutic use. In some embodiments, the present invention provides a method of preparing a stable lyophilized composition comprising the steps of adding ascorbic acid to an aqueous solution comprising one or more lipid nanoparticles, freezing the aqueous solution to obtain a frozen solution, drying the frozen solution to obtain a lyophilized composition, and increasing and holding the temperature of the lyophilized composition to a temperature of between 15° C. to 30° C.